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Coronary Arteries: Role of Voltage-Gated Potassium
Channel Activation
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Abstract: Relaxation and changes in the transmembrane potential
of vascular smooth muscle induced by ORM-3819, a novel inodilat-
ing compound, were investigated in isolated porcine coronary
arteries. Isometric tone was studied on arterial rings precontracted
by KCl (30 mM), and resting membrane potential was investigated
by a conventional microelectrode technique. ORM-3819 in the
concentration range 0.38–230.6 mM evoked concentration-
dependent relaxation with a maximum value of 58.1% and an effec-
tive concentration of the relaxing substance that caused 50% of
maximum relaxation of 72.2 mM. The maximum hyperpolarization
produced by ORM-3819 at a concentration of 120 mM (22.66 0.81
mV, N = 10) did not differ signiﬁcantly from that induced by C-type
natriuretic peptide (CNP), an endogenous hyperpolarizing mediator,
at a concentration of 1.4 mM (23.6 6 0.38 mV, N = 17). The same
effect elicited by the known inodilator levosimendan was less pro-
nounced at a concentration of 3.7 mM:21.826 0.44 mV, N = 22 (P
, 0.05 vs. CNP). The voltage-gated potassium channel inhibitor 4-
aminopyridine, at a concentration of 5 mM, attenuated the relaxation
induced by ORM-3819 at concentrations of 41.6 or 117.2 mM. These
results suggest that ORM-3819 is a potent vasodilating agent able to
relieve coronary artery vasospasm by causing hyperpolarization of
vascular smooth muscle cells through processes involving activation
of voltage-gated potassium channels.
Key Words: inodilator, hyperpolarization, vasodilation, coronary
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INTRODUCTION
It has been suggested that a positive inotrope needs to
have a pleiotropic effect, such as peripheral vasodilation, to elicit
further beneﬁts in acute heart failure patients manifesting
hypoperfusion and congestion.1 Drugs possessing several mech-
anisms of action, such as levosimendan, have been described,
which, in addition to a positive inotropic action through calcium
sensitization,2 dilates peripheral arteries and veins.3–10 Levosi-
mendan activates potassium channels in vascular smooth muscle
(VSM) cells, a mechanism that hyperpolarizes the cell mem-
brane and causes relaxation.11 We demonstrated the direct vaso-
dilating effect of levosimendan in porcine and human coronary
artery preparations and suggested a hyperpolarizing mechanism
of the inodilating drug through activation of potassium channels
other than those modulated by adenosine triphosphate.8,12
Hyperpolarization of the membrane of smooth muscle
cells closes voltage-dependent calcium channels and results in
a decrease in vascular tone.13 This represents an endogenous
vasodilating mechanism that is independent of endothelium-
derived nitric oxide in large epicardial coronary arteries under
experimental conditions.14–16 One candidate endogenous hy-
perpolarizing factor in the coronary arteries is C-type natri-
uretic peptide (CNP), which is present in atherosclerotic
coronary artery tissue and exerts a vasodilating effect in the
presence of damaged endothelium.17–21
We have recently studied the effect of a new inodilator,
ORM-3819, which acts through 2 mechanisms: (1) calcium
sensitization and (2) highly speciﬁc phosphodiesterase III
inhibition.22 The positive inotropic effect of this novel chemical
entity was recently demonstrated both in vitro and in vivo,22 but
the potential effect of this compound on vascular tone and the
mechanism underpinning that effect remain unrevealed.
The present investigation, performed in isolated porcine
coronary arteries, was devised to determine the efﬁcacy of
ORM-3819 in decreasing vascular tone, to compare its
hyperpolarizing effect with those of CNP and levosimendan
and to explore the involvement of the voltage-gated potas-
sium channel (Kv) in those effects.
METHODS
Tissue Preparation
Coronary arteries were obtained from porcine hearts
harvested at a local abattoir. All animals received humane
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care in accordance with the Guide for the Care and Use of
Laboratory Animals. The experimental protocol was
approved by the ethical review board of the University of
Szeged, Szeged, Hungary (approval no. XIII/1211/2012).
After harvesting, hearts were placed in ice-cold Krebs–
Henseleit solution (see composition described below) and
transported to the laboratory within 1 hour. Coronary arteries
of the circumﬂex branch were dissected free from the sur-
rounding connective tissue and cut into 5-mm-long rings
while maintained in ice-cold Krebs–Henseleit solution.
Measurements of Isometric Tone
Ring segments were mounted on a pair of stainless-steel
hooks and placed in water-thermostated (378C) organ cham-
bers containing 2 mL of Krebs–Henseleit solution. The
solution was continuously bubbled with a mixture of 95% O2
and 5% CO2 at pH 7.4. One of the hooks was anchored inside
the organ chamber, and the other was connected to a force-
displacement transducer (Experimetria, Budapest, Hungary)
to measure changes in isometric tension. Mechanical re-
sponses of the arterial rings were recorded by means of
a pen recorder (Type 175; KUTESZ, Budapest, Hungary) as
described previously.15 The rings were stretched up to a ten-
sion of 29.4 mN and equilibrated for 90 minutes. During this
period, the tension was continuously readjusted to 29.4 mN,
and the medium was refreshed every 15 minutes.
Protocol for Studying the Effect of ORM-3819
on Isometric Tone
All the experiments were performed using intact
vascular samples isolated from the same porcine hearts.
Coronary artery rings were contracted with 30 mM KCl.
When the contraction reached a stable plateau, ORM-3819
was administered at 5 stepwise increasing concentrations
(0.38–230.6 mM; N = 7) into the organ baths. In a separate
group of experiments, the effect of the solvent was investi-
gated (N = 7). The effects of the “solvent alone” were always
measured, and those values subtracted from the “solvent and
agent” measured values at each set of data.
Measurements of Resting Membrane
Potential
A ring segment of the coronary artery was prepared as
described previously, slit longitudinally, and pinned to the
Sylgard base of a 0.5-mL chamber with the intimal surface
upward. The isolated vascular segments were continuously
superfused with Krebs–Henseleit solution aerated with 95%
O2 and 5% CO2 at a constant rate of 2 mL/min, and the
temperature was maintained at 378C (pH 7.4).
The transmembrane potential of smooth muscle cells
was measured using a conventional microelectrode technique.
An intracellular glass microelectrode ﬁlled with 3 M KCl (tip
resistance 30–40 MV) was connected to the headstage of
a recording ampliﬁer (Intra 767; World Precision Instruments,
Sarasota, FL) with capacitance neutralization. An Ag/AgCl
pellet in contact with the bathing solution and directly con-
nected to the ampliﬁer served as a reference electrode. The
signal was continuously monitored and recorded on
a paperless recorder (Type 80807; Cole-Parmer International,
Vernon Hills, IL). Microelectrodes were impaled in a smooth
muscle cell from the intimal side, and successful impalements
were signaled by a sudden negative shift in voltage, followed
by a stable negative voltage for at least 2 minutes and an
instantaneous return to the previous voltage level on dislodge-
ment of the microelectrode.
Protocol for Studying the Effects of ORM-
3819, CNP, and Levosimendan on Resting
Membrane Potential
For detecting the successful impalement of the smooth
muscle cell with the electrode, 5-mM pinacidil was added to
the organ bath. Pinacidil is known to cause hyperpolarization
in smooth muscle cells, but not endothelial cells, under rest-
ing conditions.23 Data collection was restricted to those ex-
periments, in which pinacidil exhibited a hyperpolarizing
effect.
In pinacidil-positive preparations, the resting membrane
potential of the smooth muscle cells was recorded after
equilibration for 60 minutes. CNP (1.4 mM; N = 17), ORM-
3819 (60, 120 or 180 mM; N = 14, 10, and 12, respectively),
or the known hyperpolarizing inodilator levosimendan (1.8,
3.7, or 5.5 mM; N = 18, 22, and 15, respectively) were then
added to the bath as bolus injections. The effect of solvents
were tested in case of each agent at each mentioned concen-
tration (N = 5).
Protocol for Studying the Effect of 4-
Aminopyridine (4-AP) on ORM-3819–Induced
Relaxation
Two endothelium-intact coronary artery rings were
mounted in parallel in separate organ baths. One of the rings
was pretreated with 4-AP (5 mM), while the other was
preincubated with the same volume of 4-AP solvent (20 mL
of distilled water). After 10 minutes, both rings were precon-
tracted with 30 mM KCl, and then ORM-3819 was adminis-
tered stepwise at increasing concentrations (41.6–230.6 mM).
As the solvent of ORM-3819 exerted a signiﬁcant relaxing
effect at and above volumes corresponding to 117.2 and
230.6 mM ORM-3819 (90 and 180 mL, respectively), the
mean effects of the solvent were ascertained separately and
subtracted from the effects of ORM-3819.
Drugs
The composition of Krebs–Henseleit solution (mM)
was as follows: NaCl, 120; KCl, 4.2; CaCl2, 1.5; NaHCO3,
20; MgCl2, 1.2; KH2PO4, 1.2; and glucose, 11. The compo-
nents of Krebs–Henseleit solution, including KCl, were ob-
tained from Reanal (Budapest, Hungary).
The structure of the investigational compound ORM-
3819, which has the chemical formula (L)-6-{4-[N0-(4-
hydroxy-3-methoxy-2-nitro-benzylidene)-hydrazino]-phe-
nyl}-5-methyl-4,5-dihydro-2H-pyridazin-3-one, is depicted in
Figure 1. ORM-3819 and levosimendan were obtained from
Orion-Pharma (Espoo, Finland). 4-AP, CNP, and pinacidil
were purchased from Sigma (St. Louis, MO). ORM-3819
was prepared daily by dissolving it in a solution of 50%
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ethanol (Etax AaS; Primalco, Rajamäki, Finland) in a sodium
bicarbonate buffer (NaHCO3 analytical reagent, Riedel-de-
Haën, Seelze, at pH 9.6 containing 5% D(+)-glucose (anhy-
drous for biochemistry, Merck, Darmstadt, Germany). The
concentration of the ORM-3819 stock solution was 1 mg/
mL, which was further diluted with the same solvent to reach
lower concentrations (0.1 and 0.01 mg/mL). The stock solu-
tion was stored at room temperature. Levosimendan was dis-
solved in 70% ethanol and diluted further in Krebs–Henseleit
solution. Pinacidil was prepared in 50% ethanol. 4-AP and
CNP were dissolved in distilled water. The dose range of
ORM-3819 in the current experiments was selected on the
basis of the previous experience with the in vitro and ex vivo
effects of the drug.22
Analysis of Data
The increase in basal coronary tone and the tone induced
by 30 mM KCl were expressed in millinewtons. Relaxations
caused by ORM-3819 were calculated and expressed as the
percentage of the KCl-induced steady-state contraction ampli-
tude of the same preparation. All values are reported as mean6
standard error of the mean, where N represents the number of
arterial samples tested. The effective concentration of the relax-
ing substance which caused 50% of maximum relaxation
(Emax) was deﬁned as EC50. The logistic equation (a · x)/(x
+ b) was ﬁtted to the mean values for calculating the values of
Emax (1) and EC50 (2). The Wilcoxon rank-sum test or the
Mann–Whitney–Wilcoxon test was used to determine signiﬁ-
cant differences. A linear correlation between hyperpolarization
and relaxation was investigated (y = slope; x + y = intercept).
Comparisons between samples were conducted using 1-way
analysis of variance and the Newman–Keuls multiple-range
test. P , 0.05 was considered statistically signiﬁcant.
RESULTS
Effects of ORM-3819 on Isometric Tone
ORM-3819 elicited concentration-dependent relaxation
in the isolated porcine coronary artery. Figure 2 shows the
magnitude of this relaxation, expressed as a percentage of
the KCl-induced precontraction, corrected for the relaxation
induced by the solvent. Fitting the equation (a · x)/(x + b)
to the mean values of the relaxations, the calculated maximum
relaxation (a) induced by ORM-3819 was 58.1% of KCl-
induced tone and the EC50 value (b) was 72.2 mM (Fig. 2).
Effects of ORM-3819 in Comparison With
Those of CNP and Levosimendan on the
Membrane Potential of Coronary Artery
Smooth Muscle Cells
Figures 3 and 4 (original recordings) demonstrate the
hyperpolarizing effects evoked by ORM-3819, CNP, and lev-
osimendan. Figure 4 summarizes the mean changes in mem-
brane potentials obtained from 10 to 22 independent electrode
impalements. Before addition of CNP, the resting membrane
potential of coronary smooth muscle cells was 249.9 6 0.92
mV (N = 17). CNP (1.4 mM) caused a mean hyperpolariza-
tion of 23.6 6 0.38 mV. Resting membrane potentials were
determined before administration of each concentration of
ORM-3819 (60, 120, and 180 mM). These membrane poten-
tials were 248.8 6 1.15 (N = 14), 248.8 6 0.88 (N = 10),
and 250.3 6 0.41 mV (N = 12), respectively, and the cor-
responding magnitude of changes in hyperpolarization
induced by 60, 120, and 180 mM ORM-3819 was 21.8 6
0.35, 22.6 6 0.81, and 22.3 6 0.99 mV, respectively. The
hyperpolarizing effect of 60 mM ORM-3819 was calculated
to be signiﬁcantly less than that obtained with 1.4 mM CNP.
Resting membrane potentials measured before the application
of 1.8, 3.7, and 5.5 mM levosimendan were 249.7 6 0.79 (N
= 18), 250.8 6 0.96 (N = 22), and 250.9 6 1.18 mV (N =
15), respectively. Maximum hyperpolarization by this inodi-
lator (21.82 6 0.44 mV) was obtained at 3.7 mM. All the
concentrations of levosimendan produced signiﬁcantly lower
hyperpolarizations than those obtained with CNP.
FIGURE 1. Structure of ORM-3819, a novel inodilating com-
pound.
FIGURE 2. Concentration–response relationship of the in-
odilator ORM-3819 in porcine coronary arteries. In the con-
centration range 0.38–230.6 mM, ORM-3819 relaxed coronary
arteries contracted by 30 mM KCl. The results are expressed as
percent relaxation of KCl-evoked tone and in the form mean 6
standard error of the mean, representing the net relaxing effect
of the inodilator, ie, the effect of the solvent was deducted from
that obtained with the corresponding concentration of ORM-
3819. Five to 7 experiments were performed.
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Effects of 4-AP on ORM-3819–Induced Relax-
ation
Pretreatment of the coronary preparations with 5 mM 4-
AP for 10 minutes resulted in a moderate but not signiﬁcant
enhancement of KCl-induced tone (control, 48.66 9.83 mN; 4-
AP, 73.4 6 10.29 mN; N = 5) but decreased the extent of
solvent-corrected coronary artery relaxation induced by ORM-
3819 from 44.06 8.52% to 30.36 5.17% at a concentration of
41.6 mM (P , 0.05; N = 5) and from 65.6 6 1.34% to 52.3 6
3.15% at a concentration of 117.2 mM (P , 0.05; N = 5) (Fig.
5). At the highest concentration of ORM-3819 (230.6 mM), 4-
AP did not inﬂuence relaxation (Fig. 5). 4-AP had no effect on
the relaxations induced by the solvent itself (N = 5).
Correlation Between Hyperpolarization and
Relaxation Induced by ORM-3819
The magnitude of ORM-3819–induced hyperpolariza-
tion (at a concentration of 60 mM), expressed as changes in
membrane potential in millivolts, showed a correlation with
the extent of relaxation evoked by ORM-3819 (Fig. 6). As the
effect of this dose ﬁts with the rise in the concentration–
response curve of the compound (Fig. 2), a linear correla-
tion between the individual relaxing values and hyperpolar-
ization was investigated. The equation for this correlation was
y = 13.4 · x + 18.7 (r = 0.75, P , 0.01). The 4-AP–induced
decrease in ORM-3819–evoked relaxation was calculated
from the values obtained during the interaction of the 2
substances and found to be 1/3.2 of the relaxation produced
by ORM-3819 alone. The slope value (13.4) divided by 3.2
shows that 1-mV hyperpolarization is responsible for 4.2% of
relaxation. The intercept indicated that this relation is valid
only above 18.7% relaxation by ORM-3819 (Fig. 6).
DISCUSSION
We demonstrated the coronary artery-dilating effect of
ORM-3819 in vitro in partially depolarizing KCl solution.
The potency of ORM-3819 was lower than that of the
inodilator levosimendan under comparable experimental
conditions.8,12 Hyperpolarization induced by ORM-3819
was compared with that induced by levosimendan and
CNP, an endogenous vasoactive regulator. The maximum
increase in resting membrane potential induced by ORM-
3819 was similar to that obtained with CNP, while the effect
of levosimendan was smaller than that of CNP.
Hyperpolarization is an efﬁcient vasodilating mecha-
nism regulating the tension of conduit-type coronary ar-
teries.24 A nitric oxide– and prostaglandin-independent
endothelium-derived hyperpolarizing factor (EDHF) has been
demonstrated in the regulation of porcine, canine, and human
coronary artery tones.14,15,24,25 EDHF has been proposed to
relax coronary arteries in experimental heart failure and cor-
onary angioplasty under pathological conditions in which ni-
tric oxide production is impaired.26–28 These ﬁndings provide
a basis and rationale for the development of hyperpolarizing
coronary artery vasodilators.
ORM-3819 is a somewhat less potent vasodilator than
levosimendan. However, the maximum hyperpolarizing effect
of ORM-3819 is larger than that measured with levosimen-
dan. The effects of both synthetic inodilators were compared
with those of CNP because this natriuretic peptide has been
FIGURE 3. Original recordings of hyperpolarization in smooth
muscle cells of porcine epicardial coronary arteries induced by
CNP, ORM-3819, and levosimendan. Resting membrane po-
tentials are depicted from 3 independent impalements. These
values were 249.2, 249.2, and 249.0 mV before addition of
CNP, ORM-3819, and levosimendan, respectively. CNP, an
endogenous hyperpolarizing mediator, served as reference
compound. CNP caused a maximum 23.7 mV change in
resting membrane potential. ORM-3819 exerted a maximum
change of 22.8 mV at a concentration of 120 mM. Levosi-
mendan, a known hyperpolarizing inodilator, resulted in
a change in membrane potential of 22.2 mV at a concentra-
tion of 3.7 mM.
FIGURE 4. Changes in resting membrane poten-
tial in vascular smooth muscle cells of porcine
epicardial coronary arteries after administration of
CNP, ORM-3819, and levosimendan. Values are
expressed in the form mean 6 standard error of
the mean, representing hyperpolarizations of
1.4 mM CNP (N = 17), 60 mM ORM-3819 (N =
14), 120 mM ORM-3819 (N = 10), 180 mM ORM-
3819 (N = 12), 1.8 mM levosimendan (N = 18),
3.7 mM levosimendan (N = 22), and 5.5 mM lev-
osimendan (N = 15). The effect of the solvent was
deducted from that obtained with the corre-
sponding concentration of ORM-3819. *P , 0.05
compared with the effect of the reference com-
pound, CNP.
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shown to act as an EDHF in rat mesenteric and human penile
resistance arteries; CNP also acts as an endothelium-
independent endogenous hyperpolarizing mediator in several
human conduit arteries.18,29,30 CNP is a potential endogenous
hyperpolarizing mediator in the epicardial coronary artery of
the pig; it also plays an important role in the pathophysiology
of human coronary arterial stenosis and in chronic heart fail-
ure.17,21,31,32 Cardiac production of CNP and expression of its
receptor, natriuretic peptide receptor B, are increased in heart
failure, suggesting that CNP is released as a cytoprotective
mechanism.33,34 Exogenous administration of CNP, in the
same concentration range that we applied in vitro (z1026
M), results in a positive lusitropic effect, an observation that
reinforces the signiﬁcance of CNP in the setting of heart
failure.35
In the porcine coronary artery, the maximum response
to CNP was 23.3 mV at a concentration of 1.4 mM.36 The
hyperpolarization induced by 1.4 mM CNP in this study
(mean 23.6 mV) is comparable with those obtained in other
experiments with this peptide (z24 to 25 mV) or with the
adenosine triphosphate–sensitive potassium channel opener
levcromakalim (z24 mV).17,37 Therefore, we only used this
concentration of CNP as a control for comparing the mag-
nitude of hyperpolarization induced by ORM-3819 or
levosimendan.
Our investigations have produced the ﬁrst evidence that
at the maximal vasorelaxing concentrations of levosimendan,8
z1–3 mM, it hyperpolarizes the large epicardial coronary
artery. Similar concentrations of levosimendan have previously
been reported to hyperpolarize resistance arteries (EC50 =
2.9 mM).11 It is important to note, however, that the magnitude
of hyperpolarization is much less in our epicardial coronary
artery preparations than in resistance arteries.11,29 Some milli-
volt changes in the membrane potential might considerably
inﬂuence vascular tone. In this study, observations on the
correlation between the hyperpolarizing and relaxing effects of
ORM-3819 showed that an increase in membrane potential of
1 mV corresponded to a relaxation of 4.2%. This value is close
to that found in rat mesenteric artery (4.3%/mV).38
ORM-3819, as levosimendan, could also have pleio-
tropic effects in addition to the inﬂuence on the voltage-gated
potassium channels, causing hyperpolarization and thus
vasodilation, KATP-channel opening, ampliﬁcation of BKCa
channel function, and/or phosphodiesterase inhibition being
the most probable ones. With the present research, we dem-
onstrated the role of voltage-gated potassium channel activa-
tion in the vasodilatory effects of ORM-3819.
In the porcine coronary artery, voltage-gated potassium
channels regulate tone both at rest and under stimulated
conditions.39,40 ORM-3819 seems to trigger the activation of
4-AP–sensitive voltage-gated potassium channels. In this
respect, the drug resembles levosimendan.41 4-AP–sensitive
potassium channels have been proposed to play a role in the
vasomotor tone of coronary arteries under pathological con-
ditions.42 Both ORM-3819 and levosimendan have been
shown to elicit beneﬁcial hemodynamic effects in canine
pathological cardiac models22,43 and, in the case of levosi-
mendan, in human severe heart failure.44–46 The activation of
voltage-gated potassium channels is signiﬁcantly involved in
the vasodilatory mechanism induced by ORM-3819. The
hyperpolarizing property of this new compound on arterial
vessel walls, at concentrations close to the EC50 value, sug-
gests the involvement of other important ionic mechanism(s)
that beneﬁcially inﬂuence the vascular tone.
In our experiments, high concentration of KCl would
attenuate the hyperpolarizing and relaxant effect of ORM-
3819 by abolishing the Kv channel–related effects—in case,
ORM-3819 was to be a selective Kv channel opener. Such
experiments are warranted to reveal other possible mecha-
nism(s) involved in the effect of ORM-3819. Such further
studies aimed to complete the characterization of the vaso-
dilatory effects of the new drug candidate, including patch-
FIGURE 5. Influence of 4-aminopyridine (4-AP) on ORM-
3819–induced relaxation of porcine epicardial coronary ar-
teries. Relaxation by ORM-3819, at concentrations of 41.6 and
117.2 mM, was decreased by the voltage-gated potassium
channel blocker, 4-AP, at a concentration of 5 mM. The effect
of the solvent was subtracted from the relaxing effect of ORM-
3819 at the concentrations studied (4-AP had no effect on the
solvent). The results are expressed as percent relaxation of
30 mM KCl-evoked tone and in the form mean 6 standard
error of the mean, representing 5 experiments for each con-
centration of ORM-3819. *P, 0.05 for the difference between
the effects of ORM-3819 and ORM-3819 + 4-AP.
FIGURE 6. Correlation between hyperpolarization and relax-
ation induced by ORM-3819 in the isolated porcine coronary
artery. The magnitude of hyperpolarization showed a positive
correlation with relaxation induced by 60 mM ORM-3819 (r =
0.75, P , 0.01). Individual values are from the same coronary
artery samples.
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clamp studies with isolated coronary VSM cells, would cor-
roborate that the ORM-induced increase in outward potas-
sium current is indeed due predominantly to Kv channel
activation.
A word or 2 have to be spent on the possible role of
cAMP in the ORM-3819–induced vasodilation. cAMP in-
duces vasodilatation when produced in VSM cells,47 and both
BKCa and Kv potassium channels are involved in cAMP-
induced vasodilation.48 The level of cAMP is regulated
through the control of both synthesis and degradation, with
the latter being controlled by PDE3A and PDE4 in VSM
cells. The phosphodiesterase inhibitor and inodilator milri-
none were indeed shown to interfere with the BKCa
channels.49
In a previous article,22 we tested the PDE inhibitory
effect of ORM-3819 on puriﬁed PDEIII and PDEIV isozymes
and found that ORM-3819 is a very selective inhibitor of
PDEIII, with a selectivity versus PDEIV of more than
12,000-fold. In comparison, such selectivity was 8000 for
levosimendan50 but only 14 for milrinone (see Table 2 on
page 11 in de Cheffoy de Courcelles et al51). As stated by
Szilágyi et al regarding levosimendan,50 both PDEIII and
PDEIV have the power to prevent intracellular cAMP accu-
mulation. Therefore, to achieve an increase of cAMP (with all
its consequences), both isozymes need to be blocked. At ther-
apeutic doses, levosimendan fails to inhibit PDEIV, and sev-
eral reports have in fact shown that levosimendan does not
increase the intracellular Ca2+ concentration to levels high
enough to account fully for the drug’s positive inotropic or
vasodilatory effects.52–55
Being as the PDEIII and PDEIV IC50 values of ORM-
3819 are in the same range as the levosimendan values, and
being as the PDEIII versus PDEIV selectivity of ORM-3819
is 1.5-fold the one found for levosimendan, we are not
expecting ORM-3819 to induce an accumulation of cAMP,
which would participate in BKCa and Kv potassium channel
activation. Nevertheless, we cannot fully discount this
possibility, and we warrant for further studies to investigate
a possible contribution of PDE inhibition on the vasodilatory
effect of ORM-3819.
CONCLUSIONS
ORM-3819 is structurally and functionally similar to
levosimendan and shares its main mechanisms of action,
including—as we hereby demonstrated—the vasodilatory
one. This, in conjunction with the positive inotropic property
of ORM-3819, may be relevant to its therapeutic potential in
ischemic heart disease. Different magnitude of
hyperpolarization/relaxation may be advantageous during
development of agents with different pleiotropic effects.
Finally, despite both the structure and the pharmacology of
ORM-3819 and levosimendan are related, the pharmacoki-
netic behavior of the molecules differs considerably, thus
justifying a development plan for a better drug.
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